Co-Operativity Between MYC and BCL-2 Pro-Survival Proteins in Cancer

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Apr 3

PMID 33799592

Citations 17

Authors

Walter Douglas Fairlie

Erinna F Lee

Affiliations

Soon will be listed here.

Abstract

B-Cell Lymphoma 2 (BCL-2), c-MYC and related proteins are arguably amongst the most widely studied in all of biology. Every year there are thousands of papers reporting on different aspects of their biochemistry, cellular and physiological mechanisms and functions. This plethora of literature can be attributed to both proteins playing essential roles in the normal functioning of a cell, and by extension a whole organism, but also due to their central role in disease, most notably, cancer. Many cancers arise due to genetic lesions resulting in deregulation of both proteins, and indeed the development and survival of tumours is often dependent on co-operativity between these protein families. In this review we will discuss the individual roles of both proteins in cancer, describe cancers where co-operativity between them has been well-characterised and finally, some strategies to target these proteins therapeutically.

Citing Articles

BCL2i-Based Therapies and Emerging Resistance in Chronic Lymphocytic Leukemia.

Li W, Atalla E, Dong J, Konopleva M Cells. 2024; 13(22).

PMID: 39594670 PMC: 11592612. DOI: 10.3390/cells13221922.

BET inhibitors (BETi) influence oxidative phosphorylation metabolism by affecting mitochondrial dynamics leading to alterations in apoptotic pathways in triple-negative breast cancer (TNBC) cells.

Rossi T, Iorio E, Chirico M, Pisanu M, Amodio N, Gallo Cantafio M Cell Prolif. 2024; 57(12):e13730.

PMID: 39223828 PMC: 11628750. DOI: 10.1111/cpr.13730.

Emerging connectivity of programmed cell death pathways and pulmonary vascular remodelling during pulmonary hypertension.

Yuan M, Liu T, Cai A, Zhan Z, Cheng Y, Wang Q J Cell Mol Med. 2024; 28(16):e70003.

PMID: 39153207 PMC: 11330287. DOI: 10.1111/jcmm.70003.

Inhibitory effect of miR-377 on the proliferative and invasive behaviors of prostate cancer cells through the modulation of MYC mRNA via its interaction with BCL-2/Bax, PTEN, and CDK4.

Azimi Y, Hajibabaei S, Azimi G, Rahimi-Jamnani F, Azizi M Genes Cancer. 2024; 15:28-40.

PMID: 38756697 PMC: 11098572. DOI: 10.18632/genesandcancer.236.

Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells.

Zeuner S, Vollmer J, Sigaud R, Oppermann S, Peterziel H, ElHarouni D J Neurooncol. 2024; 166(1):99-112.

PMID: 38184819 PMC: 10824805. DOI: 10.1007/s11060-023-04526-w.

References

Hussain S, Cheney C, Johnson A, Lin T, Grever M, Caligiuri M . Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin Cancer Res. 2007; 13(7):2144-50. DOI: 10.1158/1078-0432.CCR-06-2294. View

Zindy F, Eischen C, Randle D, Kamijo T, Cleveland J, Sherr C . Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 1998; 12(15):2424-33. PMC: 317045. DOI: 10.1101/gad.12.15.2424. View

Guo J, Li T, Schipper J, Nilson K, Fordjour F, Cooper J . Sequence specificity incompletely defines the genome-wide occupancy of Myc. Genome Biol. 2014; 15(10):482. PMC: 4242493. DOI: 10.1186/s13059-014-0482-3. View

Baluapuri A, Wolf E, Eilers M . Target gene-independent functions of MYC oncoproteins. Nat Rev Mol Cell Biol. 2020; 21(5):255-267. PMC: 7611238. DOI: 10.1038/s41580-020-0215-2. View

Morton J, Sansom O . MYC-y mice: from tumour initiation to therapeutic targeting of endogenous MYC. Mol Oncol. 2013; 7(2):248-58. PMC: 5528411. DOI: 10.1016/j.molonc.2013.02.015. View

Chen L, Willis S, Wei A, Smith B, Fletcher J, Hinds M . Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005; 17(3):393-403. DOI: 10.1016/j.molcel.2004.12.030. View

Gomez-Roman N, Grandori C, Eisenman R, White R . Direct activation of RNA polymerase III transcription by c-Myc. Nature. 2003; 421(6920):290-4. DOI: 10.1038/nature01327. View

Wagner A, Small M, Hay N . Myc-mediated apoptosis is blocked by ectopic expression of Bcl-2. Mol Cell Biol. 1993; 13(4):2432-40. PMC: 359564. DOI: 10.1128/mcb.13.4.2432-2440.1993. View

Lee E, Harris T, Tran S, Evangelista M, Arulananda S, John T . BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. Cell Death Dis. 2019; 10(5):342. PMC: 6482196. DOI: 10.1038/s41419-019-1568-3. View

10.

Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W . c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell. 2012; 151(1):68-79. PMC: 3471363. DOI: 10.1016/j.cell.2012.08.033. View

11.

Hartl M . The Quest for Targets Executing MYC-Dependent Cell Transformation. Front Oncol. 2016; 6:132. PMC: 4889588. DOI: 10.3389/fonc.2016.00132. View

12.

Jacobsen K, Prasad V, Sidman C, OSMOND D . Apoptosis and macrophage-mediated deletion of precursor B cells in the bone marrow of E mu-myc transgenic mice. Blood. 1994; 84(8):2784-94. View

13.

Cimmino A, Calin G, Fabbri M, Iorio M, Ferracin M, Shimizu M . miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005; 102(39):13944-9. PMC: 1236577. DOI: 10.1073/pnas.0506654102. View

14.

Oltersdorf T, Elmore S, Shoemaker A, Armstrong R, Augeri D, Belli B . An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005; 435(7042):677-81. DOI: 10.1038/nature03579. View

15.

Roussel M, Saule S, Lagrou C, Rommens C, Beug H, Graf T . Three new types of viral oncogene of cellular origin specific for haematopoietic cell transformation. Nature. 1979; 281(5731):452-5. DOI: 10.1038/281452a0. View

16.

Alqahtani A, Choucair K, Ashraf M, Hammouda D, Alloghbi A, Khan T . Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy. Future Sci OA. 2019; 5(3):FSO372. PMC: 6426170. DOI: 10.4155/fsoa-2018-0115. View

17.

Masso-Valles D, Soucek L . Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc. Cells. 2020; 9(4). PMC: 7226798. DOI: 10.3390/cells9040883. View

18.

Carra G, Nicoli P, Lingua M, Maffeo B, Cartella A, Circosta P . Inhibition of bromodomain and extra-terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia. J Cell Mol Med. 2019; 24(2):1650-1657. PMC: 6991693. DOI: 10.1111/jcmm.14857. View

19.

Adams C, Mitra R, Gong J, Eischen C . Non-Hodgkin and Hodgkin Lymphomas Select for Overexpression of BCLW. Clin Cancer Res. 2017; 23(22):7119-7129. PMC: 5700812. DOI: 10.1158/1078-0432.CCR-17-1144. View

20.

Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno A, Le Toumelin-Braizat G . The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016; 538(7626):477-482. DOI: 10.1038/nature19830. View